Evidence map›Paper›PMID 38630386›Full record

ArticleJournal of neuro-oncology2024

Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.

Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Sylvia Adams, Brandon Santhumayor, Ying Meng, Zane Schnurman, Bernadine R Donahue, Kenneth Bernstein, Cordelia Orillac and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Elad MashiachDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA. elad.mashiach@nyulangone.org.
Juan Diego AlzateDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Fernando De Nigris VasconcellosDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Sylvia AdamsPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Brandon SanthumayorDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Ying MengDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Zane SchnurmanDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Bernadine R DonahueDepartment of Radiation Oncology, NYU Langone Health, New York University, New York, NY, USA.
Kenneth BernsteinDepartment of Radiation Oncology, NYU Langone Health, New York University, New York, NY, USA.
Cordelia OrillacDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Rishitha BollamPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Maryann J KwaPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Marleen MeyersPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Ruth OratzPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Yelena NovikPerlmutter Cancer Center, NYU Langone Health, New York University, New York, NY, USA.
Joshua S SilvermanDepartment of Radiation Oncology, NYU Langone Health, New York University, New York, NY, USA.
David H HarterDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
John G GolfinosDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Douglas KondziolkaDepartment of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.
Neurological Surgery · USNYU Langone Health · USMaimonides Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough ongoing studies are assessing the efficacy of new systemic therapies for patients with triple negative breast cancer (TNBC), the overwhelming majority have excluded patients with brain metastases (BM). Therefore, we aim to characterize systemic therapies and outcomes in a cohort of patients with TNBC and BM managed with stereotactic radiosurgery (SRS) and delineate predictors of increased survival.

methodsWe used our prospective patient registry to evaluate data from 2012 to 2023. We included patients who received SRS for TNBC-BM. A competing risk analysis was conducted to assess local and distant control.

resultsForty-three patients with 262 tumors were included. The median overall survival (OS) was 16 months (95% CI 13-19 months). Predictors of increased OS after initial SRS include Breast GPA score > 1 (p < 0.001) and use of immunotherapy such as pembrolizumab (p = 0.011). The median time on immunotherapy was 8 months (IQR 4.4, 11.2). The median time to new CNS lesions after the first SRS treatment was 17 months (95% CI 12-22). The cumulative rate for development of new CNS metastases after initial SRS at 6 months, 1 year, and 2 years was 23%, 40%, and 70%, respectively. Thirty patients (70%) underwent multiple SRS treatments, with a median time of 5 months (95% CI 0.59-9.4 months) for the appearance of new CNS metastases after second SRS treatment.

conclusionsTNBC patients with BM can achieve longer survival than might have been previously anticipated with median survival now surpassing one year. The use of immunotherapy is associated with increased median OS of 23 months.

Indexed as

Brain NeoplasmsRadiosurgeryTriple Negative Breast NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMiddle AgedPrognosisProspective StudiesRegistriesSurvival RateTreatment OutcomeBrain metastasesBreast cancerGamma knifeImmunotherapyNeuro oncologyStereotactic radiosurgeryTriple negative breast cancer

Identifiers

PMID38630386
OpenAlexW4394873522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.